Fabry Disease Market Research Report โ€“ Forecast till 2030

Fabry Disease Market Research Report: by type (type-1 and type-2), diagnosis treatment (diagnosis (blood test, urine test, imaging, others, treatment (Enzyme Replacement and Gene Therapy, Anticonvulsants, others))), by end user - Forecast Till 2030

ID: MRFR/HC/5599-HCR | January 2023 | Region: Global | 90 Pages         

Table of Contents:


Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Macroeconomic Indicators

4.5 Pipeline Products

Chapter 5. Market Factor Analysis

5.1 Porterโ€™s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Fabry Disease Market, by Type

6.1 Introduction

6.2 Type 1 Fabry Disease

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3 Type 2 Fabry Disease

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 7. Global Fabry Disease Market, by Diagnosis & Treatment

7.1 Introduction

7.2 Diagnosis

7.2.1 Blood Test

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.2 Urine Test

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.3 Thyroid Test

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.4 Lung Function Test

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.5 Imaging

7.2.5.1 Electrocardiogram (EKG)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.5.2 Echocardiogram

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.5.3 Brain MRI

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.5.4 CT Scan

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.5.5 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.6 Hearing and Eye Examination

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.7 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3 Treatment

7.3.1 Enzyme Replacement Therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.2 Gene Therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.3 Pharmaceutical Formulations Containing Agalsidase Alfa

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.4 Analgesics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.5 Anticonvulsants

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.6 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.7 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 8. Global Fabry Disease Market, by End User

8.1 Introduction

8.2 Hospitals & Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3 Diagnostic Centers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4 Research & Academic Institutes

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.5 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 9. Global Fabry Disease Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 AMGEN INC.

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 AMICUS THERAPEUTICS, INC.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 BRISTOL-MYERS SQUIBB COMPANY

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 GlaxoSmithKline

11.4.1 Company Overview

11.4.2 Product Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 IBio, Inc.

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Neuraltus Pharmaceuticals, Inc.

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Novartis AG

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 PFIZER INC.

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Sanofi

11.9.1 Overview

11.9.2 Product Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Shire

11.10.1 Overview

11.10.2 Product Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 Takeda Pharmaceutical Company Limited

11.11.1 Overview

11.11.2 Product Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 Teva Pharmaceutical Industries Ltd

11.12.1 Overview

11.12.2 Product Overview

11.12.3 Financials

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.13 AVROBIO, Inc.

11.13.1 Overview

11.13.2 Product Overview

11.13.3 Financials

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.14 Idorsia Pharmaceuticals Ltd

11.14.1 Overview

11.14.2 Product Overview

11.14.3 Financials

11.14.4 Key Developments

11.14.5 SWOT Analysis

11.15 Protalix

11.15.1 Overview

11.15.2 Product Overview

11.15.3 Financials

11.15.4 Key Developments

11.15.5 SWOT Analysis

11.16 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEOโ€™s View point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Predictions for the Fabry Disease Industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Global Fabry Disease Market Synopsis, 2020-2027

Table 2 Global Fabry Disease Market Estimates and Forecast, 2020-2027 (USD Million)

Table 3 Global Fabry Disease Market, by Region, 2020-2027 (USD Million)

Table 4 Global Fabry Disease Market, by Type, 2020-2027 (USD Million)

Table 5 Global Fabry Disease Market, by Diagnosis & Treatment, 2020-2027 (USD Million)

Table 6 Global Fabry Disease Market, by End User, 2020-2027 (USD Million)

Table 7 North America: Fabry Disease Market, by Type, 2020-2027 (USD Million)

Table 8 North America: Fabry Disease Market, by Diagnosis & Treatment, 2020-2027 (USD Million)

Table 9 North America: Fabry Disease Market, by End User, 2020-2027 (USD Million)

Table 10 US: Fabry Disease Market, by Type, 2020-2027 (USD Million)

Table 11 US: Fabry Disease Market, by Diagnosis & Treatment, 2020-2027 (USD Million)

Table 12 US: Fabry Disease Market, by End User, 2020-2027 (USD Million)

Table 13 Canada: Fabry Disease Market, by Type, 2020-2027 (USD Million)

Table 14 Canada: Fabry Disease Market, by Diagnosis & Treatment, 2020-2027 (USD Million)

Table 15 Canada: Fabry Disease Market, by End User, 2020-2027 (USD Million)

Table 16 South America: Fabry Disease Market, by Type, 2020-2027 (USD Million)

Table 17 South America: Fabry Disease Market, by Diagnosis & Treatment, 2020-2027 (USD Million)

Table 18 South America: Fabry Disease Market, by End User, 2020-2027 (USD Million)

Table 19 Europe: Fabry Disease Market, by Type, 2020-2027 (USD Million)

Table 20 Europe: Fabry Disease Market, by Diagnosis & Treatment, 2020-2027 (USD Million)

Table 21 Europe: Fabry Disease Market, by End User, 2020-2027 (USD Million)

Table 22 Western Europe: Fabry Disease Market, by Type, 2020-2027 (USD Million)

Table 23 Western Europe: Fabry Disease Market, by Diagnosis & Treatment, 2020-2027 (USD Million)

Table 24 Western Europe: Fabry Disease Market, by End User, 2020-2027 (USD Million)

Table 25 Eastern Europe: Fabry Disease Market, by Type, 2020-2027 (USD Million)

Table 26 Eastern Europe: Fabry Disease Market, by Diagnosis & Treatment, 2020-2027 (USD Million)

Table 27 Eastern Europe: Fabry Disease Market, by End User, 2020-2027 (USD Million)

Table 28 Asia-Pacific: Fabry Disease Market, by Type, 2020-2027 (USD Million)

Table 29 Asia-Pacific: Fabry Disease Market, by Diagnosis & Treatment, 2020-2027 (USD Million)

Table 30 Asia-Pacific: Fabry Disease Market, by End User, 2020-2027 (USD Million)

Table 31 Middle East & Africa: Fabry Disease Market, by Type, 2020-2027 (USD Million)

Table 32 Middle East & Africa: Fabry Disease Market, by Diagnosis & Treatment, 2020-2027 (USD Million)

Table 33 Middle East & Africa: Fabry Disease Market, by End User, 2020-2027 (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Market Structure for Global Fabry Disease Market

Figure 3 Market Dynamics for Global Fabry Disease Market

Figure 4 Global Fabry Disease Market Share, by Type, 2020

Figure 5 Global Fabry Disease Market Share, by Diagnosis & Treatment, 2020

Figure 6 Global Fabry Disease Market Share, by End User, 2020

Figure 7 Global Fabry Disease Market Share, by Region, 2020

Figure 8 North America: Fabry Disease Market Share, by Country, 2020

Figure 9 Europe: Fabry Disease Market Share, by Country, 2020

Figure 10 Asia-Pacific: Fabry Disease Market Share, by Country, 2020

Figure 11 Middle East & Africa: Fabry Disease Market Share, by Country, 2020

Figure 12 Global Fabry Disease Market: Company Share Analysis, 2020 (%)

Figure 13 AMGEN INC.: Key Financials

Figure 14 AMGEN INC.: Segmental Revenue

Figure 15 AMGEN INC.: Geographical Revenue

Figure 16 AMICUS THERAPEUTICS, INC.: Key Financials

Figure 17 AMICUS THERAPEUTICS, INC.: Segmental Revenue

Figure 18 AMICUS THERAPEUTICS, INC.: Geographical Revenue

Figure 19 BRISTOL-MYERS SQUIBB COMPANY: Key Financials

Figure 20 BRISTOL-MYERS SQUIBB COMPANY: Segmental Revenue

Figure 21 BRISTOL-MYERS SQUIBB COMPANY: Geographical Revenue

Figure 22 GlaxoSmithKline: Key Financials

Figure 23 GlaxoSmithKline: Segmental Revenue

Figure 24 GlaxoSmithKline: Geographical Revenue

Figure 25 IBio, Inc.: Key Financials

Figure 26 IBio, Inc.: Segmental Revenue

Figure 27 IBio, Inc.: Geographical Revenue

Figure 28 Neuraltus Pharmaceuticals, Inc.: Key Financials

Figure 29 Neuraltus Pharmaceuticals, Inc.: Segmental Revenue

Figure 30 Neuraltus Pharmaceuticals, Inc.: Geographical Revenue

Figure 31 Novartis AG: Key Financials

Figure 32 Novartis AG: Segmental Revenue

Figure 33 Novartis AG: Geographical Revenue

Figure 34 PFIZER INC.: Key Financials

Figure 35 PFIZER INC.: Segmental Revenue

Figure 36 PFIZER INC.: Geographical Revenue

Figure 37 Sanofi: Key Financials

Figure 38 Sanofi: Segmental Revenue

Figure 39 Sanofi: Geographical Revenue

Figure 40 Shire: Key Financials

Figure 41 Shire: Segmental Revenue

Figure 42 Shire: Geographical Revenue

Figure 43 Takeda Pharmaceutical Company Limited: Key Financials

Figure 44 Takeda Pharmaceutical Company Limited: Segmental Revenue

Figure 45 Takeda Pharmaceutical Company Limited: Geographical Revenue

Figure 46 Teva Pharmaceutical Industries Ltd: Key Financials

Figure 47 Teva Pharmaceutical Industries Ltd: Segmental Revenue

Figure 48 Teva Pharmaceutical Industries Ltd: Geographical Revenue

Figure 49 AVROBIO, Inc.: Key Financials

Figure 50 AVROBIO, Inc.: Segmental Revenue

Figure 51 AVROBIO, Inc.: Geographical Revenue

Figure 52 Idorsia Pharmaceuticals Ltd: Key Financials

Figure 53 Idorsia Pharmaceuticals Ltd: Segmental Revenue

Figure 54 Idorsia Pharmaceuticals Ltd: Geographical Revenue

Figure 55 Protalix: Key Financials

Figure 56 Protalix: Segmental Revenue

Figure 57 Protalix: Geographical Revenue